Sorafenib: all 509 studies that test it
Page 3 of 6. Open to participants first (13), then studies with results posted, then the rest; newest registration first within each.
- Toripalimab Plus Sorafenib in Patients With Advanced-Stage Hepatocellular CarcinomaStatus unknownNCT04926532Phase 1/2
- Sorafenib Maintenance for Prophylaxis of Leukemia Relapse in Allo-HSCT Recipients With FLT3 Negative Acute LeukemiaStatus unknownNCT04674345Phase 2/3
- Sorafenib Plus Toripalimab for Unresectable HCC With Portal Vein Tumor ThrombusStatus unknownNCT04069949Phase 1/2
- YIV-906 (Formerly PHY906/KD018) With Sorafenib in HBV(+) Hepatocellular Carcinoma (HCC)CompletedNCT04000737Phase 2
- Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME TrialTerminatedNCT03878524Phase 1
- Using Sorafenib as a Salvage Treatment for Relapsed or Refractory Acute Myeloid Leukemia Carrying FLT3-ITDCompletedNCT03622541Phase 2
- Effect of Tumor Treating Fields (TTFields, 150kHz) Concomitant with Sorafenib for Advanced Hepatocellular Carcinoma (HCC) (HEPANOVA)CompletedNCT03606590Phase 2
- CVM-1118 and Sorafenib Combination in Subjects With Advanced Hepatocellular CarcinomaTerminatedNCT03582618Phase 2
- SECOX as Neoadjuvant Therapy in Patients With Locally Advanced HCCCompletedNCT03578874Phase 2
- Nexavar for Neoadjuvant Treatment of Anaplastic Thyroid CancerCompletedNCT03565536Phase 2
- Sorafenib, Busulfan and Fludarabine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia Undergoing Donor Stem Cell TransplantActive, not recruitingNCT03247088Phase 1/2
- Combination of Sorafenib and Omacetaxine Mepesuccinate in Newly Diagnosed or Relapsed/Refractory AML Carrying FLT3-ITDCompletedNCT03170895Phase 2
- A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid LeukemiaActive, not recruitingNCT03164057Phase 2
- Palbociclib and Sorafenib, Decitabine, or Dexamethasone in Treating Patients With Recurrent or Refractory LeukemiaActive, not recruitingNCT03132454Phase 1
- Efficacy and Safety of Sorafenib as Adjuvant and Latter Radiofrequency Ablation for Recurrent Hepatocellular CarcinomaStatus unknownNCT03097848Not applicable
- Paediatric Hepatic International Tumour TrialActive, not recruitingNCT03017326Phase 3
- Sorafenib and Bavituximab Plus SBRT in Unresectable Hepatocellular CarcinomaWithdrawnNCT02989870Phase 1
- Study of Safety and Tolerability of PDR001 in Combination With Sorafenib and to Identify the Maximum Tolerated Dose and/or Phase 2 Dose for This Combination in Advanced Hepatocellular PatientsCompletedNCT02988440Phase 1
- Sorafenib Versus Best Supportive Care in Egyptian Hepatocellular Carcinoma Patients.CompletedNCT02971696Phase 3
- Sorafenib Treatment in Patients With Hepatocellular Carcinoma With Microvascular Invasion After Radical ResectionTerminatedNCT02867280Phase 3
- Sorafenib Combined With Aspirin to Prevent the Recurrence in High-risk Patients With Hepatocellular CarcinomaTerminatedNCT02748304Not applicable
- Treating Relapsed/Recurrent/Refractory Pediatric Solid Tumors With Sorafenib in Combination With IrinotecanWithdrawnNCT02747537Phase 2
- Mechanism of Sorafenib Resistance in Patients With Advanced Hepatocellular CarcinomaStatus unknownNCT02733809Phase 4
- Study to Evaluate the Safety and Efficacy of Sorafenib, in Subject With Refractory Solid TumorsWithdrawnNCT02691780Not applicable
- Genomics-Based Target Therapy for Children With Relapsed or Refractory MalignancyStatus unknownNCT02638428Phase 2
- Sorafenib Administered Using a High-dose, Pulsatile Regimen: a Phase I Exposure Escalation StudyCompletedNCT02636426Phase 1
- Bioequivalence Study of Sorafenib Tablet and NexavarCompletedNCT02599337Phase 1
- Phase II Sorafenib With Radiation and Temozolomide in Newly Diagnosed Glioblastoma or GliosarcomaWithdrawnNCT02599090Phase 2
- Relative Bioavailability of Sorafenib Tablet for Oral SuspensionCompletedNCT02538393Phase 1
- Sorafenib and TACE as Adjuvant Therapy for MVI in HCC Patients After Radical ResectionStatus unknownNCT02537158Not applicable
- TACE With or Without Sorafenib in Intermediate Stage Hepatocellular CarcinomaStatus unknownNCT02529761Not applicable
- Clinical Trial for GALNT14 Genotype - Guided, Sorafenib in Combination With TACE in Hepatocellular CarcinomaStatus unknownNCT02504983Phase 4
- Sorafenib for Prophylaxis of Leukemia Relapse in Allo-HSCT Recipients With FLT3-ITD Positive AMLCompletedNCT02474290Phase 2/3
- Single-arm Study to Evaluate the Safety and Efficacy of Sorafenib, in Subjects With BRAF Mutation Refractory Solid TumorsCompletedNCT02450149Not applicable
- Efficacy of Localized Concurrent Chemo-radiation Therapy and Sorafenib Sequential Therapy in Advanced Hepatocellular CarcinomaCompletedNCT02425605Phase 2
- Sequential Melphalan for Use With Hepatic Delivery System Treatment Followed by Sorafenib in Patients With Unresectable HCCWithdrawnNCT02406508Phase 2
- A Study of BBI608 Administrated With Sorafenib in Adult Patients With Advanced Hepatocellular CarcinomaCompletedNCT02358395Phase 1
- A Study of BBI503 in Advanced Solid Tumors, or BBI503/ Sorafenib in Advanced Hepatocellular CarcinomaCompletedNCT02354898Phase 1
- Neoadjuvant Chemotherapy Followed by Radiation Therapy and Gemcitabine/Sorafenib/Vorinostat in Pancreatic CancerCompletedNCT02349867Phase 1
- Sorafenib Drug Drug Interaction Study in Healthy Male SubjectsCompletedNCT02332031Phase 1
- Safety and Efficacy Study of CC-122 Combined With Sorafenib for Primary Liver CancerTerminatedNCT02323906Phase 1
- Efficacy and Safety of Concurrent TACE and Sorafenib in Patients With HCC and Extrahepatic Metastasis (COTSOM Study)Status unknownNCT02311205Phase 2
- Sorafenib and Cyclophosphamide/Topotecan in Patients With Relapsed and Refractory NeuroblastomaActive, not recruitingNCT02298348Phase 1
- Trametinib in Combination With Sorafenib in Patients With Advanced Hepatocellular CancerCompletedNCT02292173Phase 1
- Sorafenib Concurrent With Yttrium-90 Transarterial Radioembolization in Patients With Advanced Hepatocellular CancerWithdrawnNCT02288507Phase 1
- Crenolanib in Combination With Sorafenib in Patients With Refractory or Relapsed Hematologic MalignanciesCompletedNCT02270788Phase 1
- Sorafenib Plus Vitamin K1 Versus Sorafenib in Advanced Hepatocellular CarcinomaCompletedNCT02259647Not applicable
- A Study of LY2157299 in Participants With Unresectable Hepatocellular Cancer (HCC)CompletedNCT02240433Phase 1
- Navitoclax and Sorafenib Tosylate in Treating Patients With Relapsed or Refractory Solid TumorsCompletedNCT02143401Phase 1
- Effect of Adjuvant Therapy by Sorafenib, Oxaliplatin and S-1WithdrawnNCT02129322Phase 2
- Second Line Sorafenib After Pazopanib in Patients With RCCTerminatedNCT02122003Phase 2
- Sorafenib Phase II Study for Japanese Anaplastic or Medullary Thyroid Carcinoma PatientsCompletedNCT02114658Phase 2
- Safety and Efficacy of Sorafenib in Patients With Advanced Thyroid Cancer: a Phase II Clinical StudyCompletedNCT02084732Phase 2
- Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by SurgeryCompletedNCT02072486Not applicable
- Dose Escalation Study of OMP-54F28 in Combination With Sorafenib in Patients With Hepatocellular CancerCompletedNCT02069145Phase 1
- Sorafenib Tosylate, Cisplatin, and Docetaxel in Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and NeckCompletedNCT02035527Phase 1
- Selecting Patient-Specific Biologically Targeted Therapy for Pediatric Patients With Refractory Or Recurrent Brain TumorsStatus unknownNCT02015728Not applicable
- Sorafenib in Liver Function Impaired Advanced Hepatocellular CarcinomaCompletedNCT01932385Phase 2/3
- Refametinib in Combination With Sorafenib in RAS Mutant Hepatocellular Carcinoma (HCC)CompletedNCT01915602Phase 2
- Randomized Trial Sorafenib-Pravastatin Versus Sorafenib Alone for the Palliative Treatment of Child-Pugh A Hepatocellular CarcinomaCompletedNCT01903694Phase 3
- A Safety, Tolerability, and Pharmacokinetics Study of Onartuzumab as Single Agent or in Combination With Sorafenib in Participants With Advanced Hepatocellular CarcinomaCompletedNCT01897038Phase 1
- Sorafenib and Radioembolization With Sir-Spheres® for the Treatment of Metastatic Ocular MelanomaCompletedNCT01893099Phase 1
- Risk-Adapted Focal Proton Beam Radiation and/or Surgery in Patients With Low, Intermediate and High Risk Rhabdomyosarcoma Receiving Standard or Intensified ChemotherapyActive, not recruitingNCT01871766Phase 2
- Bortezomib, Sorafenib Tosylate, and Decitabine in Treating Patients With Acute Myeloid LeukemiaActive, not recruitingNCT01861314Phase 1
- Sorafenib and Temsirolimus in Treating Patients With Metastatic, Recurrent, or Unresectable MelanomaWithdrawnNCT01851408Phase 2
- Phase I Study With Sorafenib in Addition to Vinflunine in Metastatic Transitional Cell Carcinoma of the Urothelial TractCompletedNCT01844947Phase 1
- Sorafenib Plus Doxorubicin in Patients With Advanced Hepatocellular Carcinoma With Disease Progression on SorafenibActive, not recruitingNCT01840592Phase 2
- Phase II Open Label, Non-randomized Study of Sorafenib and Everolimus in Relapsed and Non-resectable OsteosarcomaCompletedNCT01804374Phase 2
- A Phase Ib Study of Stereotactic Body Radiotherapy (SBRT) Plus Sorafenib in Patients With Unresectable Hepatocellular Carcinoma (HCC)WithdrawnNCT01801163Phase 1
- Sorafenib Combined With Chemotherapy for Renal Collecting Duct CarcinomaCompletedNCT01762150Phase 2
- Safety and Efficacy of Oncoxin Plus Surafineb in Hepatocellular CarcinomaStatus unknownNCT01747642Phase 2/3
- Efficacy and Safety Study of Sorafenib to Treat Advanced Medullary Thyroid CarcinomaWithdrawnNCT01736878Phase 2
- Whole Brain Radiotherapy (WBRT) With Sorafenib for Breast Cancer Brain Metastases (BCBM)CompletedNCT01724606Phase 1
- Activity of Sorafenib in Salivary Gland CancerCompletedNCT01703455Phase 2
- Sorafenib and Topotecan in Refractory/Recurrent Pediatric MalignanciesCompletedNCT01683149Phase 1
- Chinese Herbal Formulation PHY906 and Sorafenib Tosylate in Treating Patients With Advanced Liver CancerCompletedNCT01666756Phase 1
- Pilot Study of Sorafenib and Bi-weekly Capecitabine in Patients With Advanced Breast and Gastrointestinal TumorsCompletedNCT01640665Phase 1
- Determination of Intratumoral Concentrations of Kinase Inhibitors in Patients With Advanced Solid Malignancies.CompletedNCT01636908Not applicable
- Sorafenib Tosylate Following a Liver Transplant in Treating Patients With Liver CancerCompletedNCT01624285Phase 2
- Radiation Therapy With Sorafenib for TACE-Resistant Hepatocellular CarcinomaWithdrawnNCT01618253Phase 1
- Phase III Sequential Open-label Study to Evaluate the Efficacy and Safety of Sorafenib Followed by Pazopanib Versus Pazopanib Followed by Sorafenib in the Treatment of Advanced / Metastatic Renal Cell Carcinoma (SWITCH-II)CompletedNCT01613846Phase 3
- Study of Curcumin, Vorinostat, and SorafenibWithdrawnNCT01608139Phase 1
- Safety, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of Sorafenib and Eribulin in CombinationCompletedNCT01585870Phase 1
- Sorafenib Tosylate Before and After Donor Bone Marrow Transplant in Treating Patients With Acute Myeloid LeukemiaCompletedNCT01578109Phase 1
- Sorafenib Plus Tegafur-uracil (UFT) Versus Sorafenib as First Line Systemic Treatment for Patients With Advanced Stage HCC, Unresectable & Not Eligible for Local Ablation and/or TACETerminatedNCT01539018Phase 2
- Vemurafenib With Sorafenib Tosylate or Crizotinib in Treating Patients With Advanced Malignancies With BRAF MutationsCompletedNCT01531361Phase 1
- Dose Escalation Study of Sorafenib and Irinotecan Combination Therapy in Pediatric Patients With Solid TumorsCompletedNCT01518413Phase 1
- Neoadjuvant Sorafenib Therapy Prior to Laser Ablation for Hepatocellular CarcinomaCompletedNCT01507064Phase 2
- Sorafenib Tosylate and Hypoxia-Activated Prodrug TH-302 in Treating Patients With Advanced Kidney Cancer or Liver Cancer That Cannot Be Removed By SurgeryCompletedNCT01497444Phase 1
- SorAfenib Versus RADIOEMBOLIZATION in Advanced Hepatocellular CarcinomaCompletedNCT01482442Phase 3
- Pemetrexed Disodium and Sorafenib Tosylate in Treating Patients With Advanced Solid TumorsCompletedNCT01450384Phase 1
- Evaluate the Efficacy of Sorafenib in Renal Cell Carcinoma Patients After a Radical Resection of the MetastasesStatus unknownNCT01444807Phase 2
- A Study Of Crizotinib Plus VEGF Inhibitor Combinations In Patients With Advanced Solid Tumors.WithdrawnNCT01441388Phase 1
- Sorafenib for Patients With Extensive KeloidsTerminatedNCT01425216Phase 2
- Palliative Treatments for Patients With Advanced Hepatocellular Carcinoma (HCC)CompletedNCT01409499Phase 4
- Sorafenib in First-line Treatment of Advanced B Child Hepatocellular CarcinomaTerminatedNCT01405573Phase 3
- Sorafenib Maintenance Therapy for Patients With AML After Allogeneic Stem Cell TransplantCompletedNCT01398501Phase 1
- Sorafenib Tosylate, Bevacizumab, Irinotecan Hydrochloride, Leucovorin Calcium, and Fluorouracil in Treating Patients With Metastatic Colorectal CancerCompletedNCT01383343Phase 1
- A Study of Sorafenib in Patients With Chemonaive Metastatic Uveal MelanomaStatus unknownNCT01377025Phase 2
- Pre-operative 5-Fluorouracil (5-FU) and Sorafenib With External Radiation in Locally Advanced Rectal CancerCompletedNCT01376453Phase 1